Controlled VH2O2 Delivery
Liquid hydrogen peroxide is vaporized and introduced under controlled pressure and temperature to create a validated sterilant concentration around the load.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Portable VHP Decontamination Systems, Fixed VHP Decontamination Systems), By Application (Hospitals, Clinics, Others), By End User (Academic & Research Institutes, Medical Device Manufacturers, Third-Party Sterilization Providers), By Technology Level (Basic Systems, Advanced Automated Systems, Connected / IoT-Enabled Systems), By Device Compatibility (Simple & Non-Lumened Devices, Complex & Lumened Devices, Robotic & Sensitive Electronic Devices), and Regional Forecast, 2026-2034
The global vaporized hydrogen peroxide decontamination systems for medical devices market was valued at USD 920.7 million in 2025 and is estimated at USD 982.4 million in 2026. The market is projected to reach USD 1,650.9 million by 2034, representing a 6.7% CAGR during 2026–2034.
Vaporized hydrogen peroxide decontamination systems use low-temperature hydrogen peroxide vapor, with or without a plasma phase, to inactivate microorganisms on medical devices and heat-sensitive instruments. Commercial systems range from compact portable units to fixed high-throughput sterilizers integrated into central sterile processing departments, device manufacturing and specialized research environments.
The regulatory position of the technology strengthened materially when FDA announced in January 2024 that vaporized hydrogen peroxide is an Established Category A sterilization method for medical devices. FDA recognition of ISO 22441:2022 provides a formal framework for development, validation and routine control, reducing the regulatory burden associated with adopting VH2O2 in 510(k) submissions compared with less-established sterilization methods.
The commercial market is also broadening through faster cycles, greater device compatibility and connected process control. STERIS markets V-PRO systems for vaporized hydrogen peroxide sterilization, ASP’s STERRAD 100NX platform supports multiple hydrogen-peroxide gas-plasma cycles including compatible endoscope processing, and Getinge introduced the Poladus 150 VH2O2 low-temperature sterilizer for heat-sensitive surgical instruments. These platforms compete on throughput, lumen claims, material compatibility, moisture management and traceable cycle documentation.
Source: FDA VHP Category A announcement; FDA medical-device sterilization; FDA ISO 22441 recognition; STERIS V-PRO s2; ASP STERRAD 100NX; Getinge Poladus 150.
The study defines the global vaporized hydrogen peroxide decontamination systems for medical devices market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Portable VHP Decontamination Systems; Fixed VHP Decontamination Systems |
| By Application | Hospitals; Clinics; Others |
| By End User | Academic & Research Institutes; Medical Device Manufacturers; Third-Party Sterilization Providers |
| By Technology Level | Basic Systems; Advanced Automated Systems; Connected / IoT-Enabled Systems |
| By Device Compatibility | Simple & Non-Lumened Devices; Complex & Lumened Devices; Robotic & Sensitive Electronic Devices |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; France; Italy; China; Japan; South Korea; India; Australia; Brazil; Mexico; GCC countries and other major markets |
| Key Market Players | STERIS plc; Advanced Sterilization Products; Ecolab / Bioquell; Getinge; Tuttnauer; Shibuya; Shinva Medical Instrument; Zhejiang TAILIN Bioengineering; Steelco; BLOCK CRS; Comecer |
The market includes capital systems that generate, control and monitor vaporized hydrogen peroxide or hydrogen-peroxide gas-plasma processes for decontamination or terminal sterilization of compatible medical devices and heat-sensitive instruments. Revenue includes portable and fixed systems together with integral control and monitoring modules.
Hydrogen peroxide consumables sold independently, room decontamination systems without a medical-device reprocessing use case, ethylene oxide sterilizers, steam sterilizers and unrelated disinfection equipment are outside the core revenue boundary unless discussed as competing technologies.
FDA now treats vaporized hydrogen peroxide as an Established Category A sterilization method for medical devices. The change supports broader use by reducing sterility-information burden in eligible 510(k) submissions.
Endoscopes, camera systems, batteries, electronics and polymer-rich instruments may not tolerate steam sterilization. VHP systems provide a low-temperature option that can preserve device integrity when validated for the specific load.
FDA explicitly positioned VH2O2 recognition within its effort to facilitate alternatives to ethylene oxide where possible. This does not make the technologies interchangeable for every device, but it expands the strategic importance of VHP in supply-chain resiliency planning.
Hydrogen peroxide concentration, diffusion, moisture and device geometry can affect sterilization performance and material durability. Manufacturers must validate cycle conditions for specific devices and cannot assume universal compatibility.
Sterile-processing departments evaluate systems on chamber size, cycle time, load weight, abort rates and device claims. Fast non-lumen cycles and flexible endoscope compatibility can materially improve instrument turnaround.
Source: FDA VHP announcement; FDA sterilization overview; STERIS s2; ASP STERRAD.
FDA’s Category A recognition and ISO 22441 framework give device manufacturers and sterilization providers a clearer regulatory basis for validated VH2O2 processes. This supports wider consideration during new-device design and sterilization-method selection.
STERIS lists a 19-minute cycle on the compact V-PRO s2, while V-PRO maX 2 and STERRAD 100NX offer multiple cycles designed around different load types. Faster validated turnaround is becoming a major competitive feature.
ASP’s ULTRA GI cycle extends STERRAD 100NX use to compatible multi-channel duodenoscopes, reflecting demand to move selected complex flexible devices from high-level disinfection toward terminal sterilization when technically feasible.
Advanced systems increasingly incorporate cycle data storage, diagnostics, hydrogen peroxide monitoring and network connectivity. Traceability supports audit readiness, quality management and instrument reprocessing documentation.
FDA recognition of updated material-compatibility guidance and standards encourages medical-device manufacturers to evaluate sterilization effects on polymers, ceramics, metals and electronics earlier in product development.
Source: STERIS V-PRO maX 2; ASP STERRAD 100NX; FDA material compatibility standard; Getinge Poladus.
VHP systems differentiate through how hydrogen peroxide is generated, distributed, monitored and removed from the chamber. Cycle design must achieve microbial lethality while protecting device materials and maintaining repeatable process control.
Liquid hydrogen peroxide is vaporized and introduced under controlled pressure and temperature to create a validated sterilant concentration around the load.
Some systems add a plasma phase that assists removal or breakdown of hydrogen peroxide after exposure, while other VHP systems operate without plasma.
Modern systems monitor pressure, temperature, peroxide concentration and other cycle parameters to confirm that validated conditions were achieved.
Networked sterilizers can store cycle records, support diagnostics and integrate with sterile-processing information systems for compliance documentation.
Source: FDA ISO 22441; STERIS s2; ASP 100NX.
By type, the market is segmented into portable and fixed VHP decontamination systems. Fixed systems are the leading segment because centralized sterile-processing and manufacturing environments require higher throughput, repeatability and permanent infrastructure.
Portable systems can be deployed where space, mobility or point-of-use flexibility is important. They are suited to smaller facilities, decentralized reprocessing and specialized decontamination tasks.
Fixed systems provide greater chamber capacity, standardized workflows and integration with central sterile-processing departments or manufacturing lines, making them the leading revenue segment.
Fixed systems will remain the largest type, while portable units provide a valuable growth niche where facilities need flexible placement, compact footprint or lower installation complexity.
By application, the market is segmented into hospitals, clinics and other settings. Hospitals are the dominant application because operating rooms and sterile-processing departments handle the largest volumes and widest variety of heat-sensitive devices.
Hospitals use VHP sterilizers for endoscopes, cameras, batteries, robotic accessories and other compatible heat-sensitive instruments. High procedural volume supports investment in fixed multi-cycle systems.
Specialty clinics and ambulatory centers require smaller systems with fast turnaround where procedure volume is meaningful but central sterile-processing infrastructure is limited.
Other settings include research laboratories, pharmaceutical environments and specialized device-processing facilities where validated low-temperature decontamination is required.
Hospitals will remain the largest application, while clinics and specialized facilities should support demand for compact, automated and lower-footprint systems.
By end user, the market is segmented into academic and research institutes, medical device manufacturers, and third-party sterilization providers. Medical device manufacturers represent a high-value segment because sterilization must be validated as part of commercial product release.
Research institutions use VHP systems for laboratory equipment, controlled environments and validation work involving sensitive devices and materials.
Manufacturers use VH2O2 for terminal sterilization or process validation of compatible finished devices, with ISO 22441 providing a formal validation framework.
Contract sterilization providers offer validated low-temperature processing to device companies and healthcare customers that do not maintain dedicated VHP capacity internally.
Medical device manufacturers should remain the most strategically important end-user growth segment as VHP gains wider design-stage consideration and regulatory familiarity.
By technology level, the market is segmented into basic systems, advanced automated systems and connected or IoT-enabled systems. Advanced automated systems lead because validated cycle control, moisture management and comprehensive data logging reduce operator variability.
Basic systems focus on controlled peroxide exposure and core cycle functionality with limited integration. They compete primarily on reliability, footprint and acquisition cost.
Advanced systems automate conditioning, sterilant delivery, aeration, diagnostics and cycle documentation, improving repeatability and operator efficiency.
Connected systems add network access, remote diagnostics, digital records and integration with instrument-tracking or sterile-processing software.
Advanced automated systems are expected to remain the leading technology level, while connected systems should gain share as hospitals prioritize traceability and digital sterile-processing workflows.
By device compatibility, the market is segmented into simple and non-lumened devices, complex and lumened devices, and robotic or sensitive electronic devices. Complex and electronic devices create the strongest value proposition because they cannot always tolerate steam sterilization.
Non-lumened instruments and surfaces are the easiest loads to validate and can benefit from very short cycles and higher load weights.
Flexible and rigid lumens require defined diameter and length limits and carefully validated cycles, creating a technically demanding but commercially important segment.
Cameras, powered instruments, batteries and robotic accessories can benefit from low-temperature processing when manufacturer instructions confirm compatibility.
Complex lumened and sensitive electronic devices will remain the principal premium opportunity because they require validated low-temperature processing and drive demand for advanced cycle claims.
Regional demand follows surgical volume, sterile-processing standards, medical-device manufacturing and capital investment. North America is the largest market, Europe is highly developed, and Asia-Pacific is the fastest-expanding regional opportunity.
North America leads through advanced sterile-processing infrastructure, large device-manufacturing activity and FDA recognition of VHP as an Established Category A method.
Europe has high adoption of sophisticated sterile-processing technology and major equipment suppliers. Medical-device regulation and infection-prevention standards support validated low-temperature processing.
China, Japan, India and South Korea are expanding hospital infrastructure, surgical volumes and domestic medical-device production, supporting both premium and value-oriented VHP systems.
Brazil and Mexico lead regional adoption as hospitals modernize sterile-processing infrastructure, but capital budgets can slow premium-system replacement.
Gulf healthcare investment supports advanced sterilization systems, while adoption elsewhere remains concentrated in tertiary hospitals and specialist centers.
Source: FDA VHP; STERIS s2; Getinge Poladus.
VHP adoption is closely tied to sterilization validation, material compatibility and the regulatory documentation used to support sterile medical devices.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Established Category A status | FDA added vaporized hydrogen peroxide to Established Category A in January 2024. | Reduces regulatory burden for eligible 510(k) submissions using a recognized sterilization method. |
| ISO 22441:2022 | FDA fully recognizes the standard covering development, validation and routine control of low-temperature VH2O2 sterilization. | Provides a common technical framework for manufacturers, sterilizer developers and processing organizations. |
| Material compatibility | FDA recognizes AAMI TIR17:2024, which includes VHP among sterilization modalities considered for material qualification. | Reinforces the need to evaluate polymers, ceramics, metals and device functionality across repeated cycles. |
| Device-specific claims | Sterilizer instructions specify permitted device types, lumen dimensions, load weights and cycle conditions. | Prevents broad assumptions of compatibility and keeps manufacturer validation central to safe use. |
Source: FDA VHP announcement; FDA ISO 22441; FDA material standard.
The competitive landscape is concentrated around established sterilization companies with large installed bases, validated device libraries and service networks. Competition is increasingly based on cycle breadth, lumen and endoscope claims, system footprint, automation, connectivity and recurring consumables.
STERIS competes through V-PRO systems spanning compact and high-capacity configurations, with differentiated cycles for non-lumen, lumen, flexible and specialty loads.
ASP’s STERRAD platform combines hydrogen peroxide vapor with gas plasma and supports a large validated device-compatibility ecosystem.
Getinge entered the modern VH2O2 segment with Poladus 150 and combines sterilization equipment with a broad sterile-processing portfolio.
Additional suppliers compete through portable systems, regional pricing, chamber design, automation and specialized application coverage.
Source: STERIS s2; ASP 100NX; Getinge Poladus.
May 2026 standards update: FDA’s recognized-standards database continued to list ISO 22441:2022 as the complete recognized standard for low-temperature vaporized hydrogen peroxide sterilization of medical devices.
2026 product cycle: ASP’s current STERRAD 100NX platform supports multiple cycles, including ULTRA GI processing for compatible multi-channel duodenoscopes, and reports more than 15 million successful cycles worldwide each year.
2026 product cycle: STERIS continues to market the V-PRO s2 and V-PRO maX 2 systems with differentiated fast, lumen, flexible and specialty cycles for heat-sensitive devices.
June 2024: Getinge launched Poladus 150, a VH2O2 low-temperature sterilizer designed for heat-sensitive surgical instruments and central sterile-processing departments.
January 2024: FDA formally moved vaporized hydrogen peroxide into Established Category A sterilization, a major regulatory milestone supporting broader medical-device adoption.
Source: FDA standards; ASP 100NX; STERIS maX 2; Getinge Poladus; FDA VHP.
The global vaporized hydrogen peroxide decontamination systems for medical devices market market is projected to grow from USD 982.4 million in 2026 to USD 1,650.9 million by 2034, at a 6.7% CAGR during 2026–2034. Growth is expected to be supported by formal regulatory recognition, rising complexity of heat-sensitive instruments, hospital sterile-processing upgrades and manufacturer interest in alternative sterilization modalities. Premium value should shift toward advanced automated systems with broader device claims and stronger digital traceability.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| FDA recognition | VH2O2 is now an Established Category A method. | Supports wider design and submission consideration. |
| Heat-sensitive devices | More instruments contain polymers, electronics and complex lumens. | Increases need for validated low-temperature sterilization. |
| EtO alternatives | Manufacturers are evaluating lower-emission alternatives where technically suitable. | Creates strategic substitution opportunities. |
| Cycle innovation | Fast and specialty cycles improve instrument turnaround. | Supports replacement of older sterilizers. |
| Connectivity | Digital records and diagnostics are becoming standard. | Raises software and service value per installed system. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global vaporized hydrogen peroxide decontamination systems for medical devices market landscape.
24LifeScience develops vaporized hydrogen peroxide decontamination systems for medical devices market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines current FDA sterilization policy, recognized consensus standards and primary manufacturer information from major VHP system suppliers. Market interpretation distinguishes validated medical-device sterilization from general environmental room decontamination and limits compatibility claims to manufacturer-defined use conditions.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 920.7 million in 2025 and is estimated at USD 982.4 million in 2026. It is projected to reach USD 1,650.9 million by 2034 at a 6.7% CAGR during 2026–2034.
It is a low-temperature process that uses hydrogen peroxide vapor, with or without a plasma phase, to sterilize compatible medical devices under validated cycle conditions.
Fixed VHP decontamination systems are the leading type because hospitals and manufacturers require repeatable, high-throughput processing.
Hospitals are the leading application because sterile-processing departments handle the largest volumes and widest range of heat-sensitive instruments.
FDA designated vaporized hydrogen peroxide an Established Category A medical-device sterilization method in January 2024.
ISO 22441:2022 provides requirements for development, validation and routine control of vaporized hydrogen peroxide sterilization processes for medical devices.
Material compatibility, lumen limits, validation complexity, capital cost and competition from steam, ethylene oxide and other low-temperature methods remain important constraints.
The study profiles STERIS, Advanced Sterilization Products, Ecolab/Bioquell, Getinge, Tuttnauer, Shibuya, Shinva, Zhejiang TAILIN, Steelco, BLOCK CRS and Comecer.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.